## Maurizio Ponz de Leon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9319301/publications.pdf

Version: 2024-02-01

189 papers 13,814 citations

53 h-index 25230 113 g-index

190 all docs

190 docs citations

190 times ranked 14420 citing authors

#	Article	IF	CITATIONS
1	Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study. Lancet Oncology, The, 2014, 15, 23-34.	5.1	1,554
2	Complications following percutaneous liver biopsy. Journal of Hepatology, 1986, 2, 165-173.	1.8	1,131
3	Mutations predisposing to hereditary nonpolyposis colorectal cancer: Database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology, 1997, 113, 1146-1158.	0.6	682
4	EUROCARE-3: survival of cancer patients diagnosed 1990–94—results and commentary. Annals of Oncology, 2003, 14, v61-v118.	0.6	638
5	Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut, 2010, 59, 975-986.	6.1	635
6	Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut, 2013, 62, 812-823.	6.1	630
7	Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut, 2008, 57, 704-713.	6.1	591
8	Identification of Lynch Syndrome Among Patients With Colorectal Cancer. JAMA - Journal of the American Medical Association, 2012, 308, 1555.	3.8	443
9	EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Annals of Oncology, 2003, 14, v128-v149.	0.6	400
10	Microsatellite Instability and Colorectal Cancer Prognosis. Clinical Cancer Research, 2005, 11, 8332-8340.	3.2	339
11	Muir-Torre syndrome. Lancet Oncology, The, 2005, 6, 980-987.	5.1	266
12	Understanding variations in survival for colorectal cancer in Europe: a EUROCARE high resolution study. Gut, 2000, 47, 533-538.	6.1	234
13	Familial occurrence of gastric cancer in the 2-year experience of a population-based registry. Cancer, 1990, 66, 2047-2051.	2.0	180
14	Cancer prevalence in European registry areas. Annals of Oncology, 2002, 13, 840-865.	0.6	164
15	Prevalence of the Y165C, G382D and 1395delGGA germline mutations of theMYH gene in Italian patients with adenomatous polyposis coli and colorectal adenomas. International Journal of Cancer, 2004, 109, 680-684.	2.3	159
16	Antioxidant vitamins or lactulose for the prevention of the recurrence of colorectal adenomas. Diseases of the Colon and Rectum, 1993, 36, 227-234.	0.7	141
17	ldentification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas. Cancer, 2005, 103, 1018-1025.	2.0	136
18	Survival of colorectal cancer patients in Europe during the period 1978–1989. European Journal of Cancer, 1998, 34, 2176-2183.	1.3	133

#	Article	IF	Citations
19	Incidence and familial occurrence of colorectal cancer and polyps in a health-care district of Northern Italy. Cancer, 1987, 60, 2848-2859.	2.0	120
20	Survival from rare cancer in adults: a population-based study. Lancet Oncology, The, 2006, 7, 132-140.	5.1	120
21	Survival differences between European and US patients with colorectal cancer: role of stage at diagnosis and surgery. Gut, 2005, 54, 268-273.	6.1	114
22	Cancer risk associated with STK11/LKB1 germline mutations in Peutz–Jeghers syndrome patients: Results of an Italian multicenter study. Digestive and Liver Disease, 2013, 45, 606-611.	0.4	113
23	Identification of hereditary nonpolyposis colorectal cancer in the general population. The 6-year experience of a population-based registry. Cancer, 1993, 71, 3493-3501.	2.0	109
24	Infliximab-related hepatitis: discussion of a case and review of the literature. Internal and Emergency Medicine, 2010, 5, 193-200.	1.0	105
25	Recommendations to improve identification of hereditary and familial colorectal cancer in Europe. Familial Cancer, 2010, 9, 109-115.	0.9	103
26	Clinical and pathologic prognostic indicators in colorectal cancer. A population-based study. Cancer, 1992, 69, 626-635.	2.0	101
27	Molecular Screening for Hereditary Nonpolyposis Colorectal Cancer: A Prospective, Population-Based Study. Journal of Clinical Oncology, 2001, 19, 3944-3950.	0.8	101
28	Effects of acute changes of bile acid pool composition on biliary lipid secretion Journal of Clinical Investigation, 1984, 74, 614-624.	3.9	99
29	Cholesterol absorption during bile acid feeding. Gastroenterology, 1980, 78, 214-219.	0.6	97
30	Suspected hereditary nonpolyposis colorectal cancer. Diseases of the Colon and Rectum, 1999, 42, 710-715.	0.7	93
31	Measuring cancer prevalence in Europe: the EUROPREVAL Project. Annals of Oncology, 2002, 13, 831-839.	0.6	88
32	The influence of age on colonic epithelial cell proliferation. Cancer, 1988, 62, 2373-2377.	2.0	85
33	Myeloperoxidase-Positive Cell Infiltration in Colorectal Carcinogenesis as Indicator of Colorectal Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2291-2297.	1.1	83
34	Survival for colon and rectal cancer in a population-based cancer registry. European Journal of Cancer, 1996, 32, 295-302.	1.3	82
35	K-ras andp53 mutations in hereditary non-polyposis colorectal cancers. International Journal of Cancer, 1997, 74, 94-96.	2.3	80
36	Hereditary nonpolyposis colorectal cancer: Review of clinical, molecular genetics, and counseling aspects., 1996, 62, 353-364.		79

#	Article	IF	CITATIONS
37	Suspected HNPCC and Amsterdam criteria II: evaluation of mutation detection rate, an international collaborative study. International Journal of Colorectal Disease, 2002, 17, 109-114.	1.0	78
38	Attenuated familial adenomatous polyposis and Muir-Torre syndrome linked to compound biallelic constitutional MYH gene mutations. Clinical Genetics, 2005, 68, 442-447.	1.0	76
39	The EUROCARE-3 database: methodology of data collection, standardisation, quality control and statistical analysis. Annals of Oncology, 2003, 14, v14-v27.	0.6	74
40	Tumour spectrum in hereditary non-polyposis colorectal cancer (HNPCC) and in families with "suspected hnpcc― A population-based study in northern Italy. International Journal of Cancer, 1993, 54, 371-377.	2.3	73
41	Histology of aberrant crypt foci in the human colon. Histopathology, 1997, 30, 328-334.	1.6	73
42	Microsatellite instability in multiple colorectal tumors. , 1999, 81, 1-5.		72
43	Colorectal carcinoma grading by quantifying poorly differentiated cell clusters is more reproducible and provides more robust prognostic information than conventional grading. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 621-628.	1.4	69
44	Mismatch repair genes and mononucleotide tracts as mutation targets in colorectal tumors with different degrees of microsatellite instability. Oncogene, 1998, 17, 157-163.	2.6	68
45	Bile lipid composition and bile acid pool size in diabetes. The American Journal of Digestive Diseases, 1978, 23, 710-716.	0.9	67
46	Characterization of MSH2 and MLH1 mutations in Italian families with hereditary nonpolyposis colorectal cancer., 1997, 18, 8-18.		67
47	Molecular Genetic Alterations and Clinical Features in Early-Onset Colorectal Carcinomas and Their Role for the Recognition of Hereditary Cancer Syndromes. American Journal of Gastroenterology, 2005, 100, 2280-2287.	0.2	66
48	The effect of chenodeoxycholic acid (CDCA) on cholesterol absorption. Gastroenterology, 1979, 77, 223-230.	0.6	65
49	Comparisons of colon–cancer survival among european countries: The eurocare study. International Journal of Cancer, 1995, 63, 43-48.	2.3	64
50	Frequency and clinical features of multiple tumors of the large bowel in the general population and in patients with hereditary colorectal carcinoma., 1996, 77, 2013-2021.		61
51	The EUROCARE II study. European Journal of Cancer, 1998, 34, 2139-2153.	1.3	61
52	Immunohistochemical Assessment of Lymphovascular Invasion in Stage I Colorectal Carcinoma. American Journal of Surgical Pathology, 2012, 36, 66-72.	2.1	58
53	K-ras AND p53 MUTATIONS IN HUMAN COLORECTAL ABERRANT CRYPT FOCI. Journal of Pathology, 1996, 178, 259-263.	2.1	57
54	Genetic testing among high-risk individuals in families with hereditary nonpolyposis colorectal cancer. British Journal of Cancer, 2004, 90, 882-887.	2.9	57

#	Article	IF	Citations
55	Cyclooxygenase-2 and Hypoxia-Inducible Factor-1î± protein expression is related to inflammation, and up-regulated since the early steps of colorectal carcinogenesis. Cancer Letters, 2009, 279, 221-229.	3.2	57
56	Trend of incidence, subsite distribution and staging of colorectal neoplasms in the 15-year experience of a specialised cancer registry. Annals of Oncology, 2004, 15, 940-946.	0.6	56
57	Influence of Small-Bowel Transit Time on Dietary Cholesterol Absorption in Human Beings. New England Journal of Medicine, 1982, 307, 102-103.	13.9	55
58	Generalized juvenile polyposis with mixed pattern and gastric cancer. Gastroenterology, 1993, 104, 910-915.	0.6	53
59	Aberrant crypt foci in patients with colorectal cancer. British Journal of Cancer, 1998, 77, 2343-2348.	2.9	53
60	Methylation pattern of different regions of the MLH1 promoter and silencing of gene expression in hereditary and sporadic colorectal cancer. Genes Chromosomes and Cancer, 2001, 31, 357-361.	1.5	53
61	Evidence for the existence of different types of large bowel tumor: Suggestions from the clinical data of a population-based registry. Journal of Surgical Oncology, 1990, 44, 35-43.	0.8	52
62	Survival analysis in families affected by hereditary non-polyposis colorectal cancer., 1997, 71, 373-376.		50
63	MLH1 and MSH2 constitutinal mutations in colorectal cancer families not meeting the standard criteria for hereditary nonpolyposis colorectal cancer., 1998, 75, 835-839.		50
64	Frequency of upper gastrointestinal lesions in patients with liver cirrhosis. Digestive Diseases and Sciences, 1988, 33, 1218-1222.	1.1	47
65	High prevalence of adenomas and microadenomas of the duodenal papilla and periampullary region in patients with familial adenomatous polyposis. European Journal of Gastroenterology and Hepatology, 1996, 8, 1201-1206.	0.8	47
66	Aberrant DNA methylation profiles of inherited and sporadic colorectal cancer. Clinical Epigenetics, 2015, 7, 131.	1.8	45
67	Prognostic significance of histological features and biological parameters in stage I (pT1 and pT2) colorectal adenocarcinoma. Pathology Research and Practice, 2006, 202, 663-670.	1.0	43
68	Involvement of <i>MBD4</i> inactivation in mismatch repair-deficient tumorigenesis. Oncotarget, 2015, 6, 42892-42904.	0.8	43
69	Effect of the selective expansion of cholic acid pool on bile lipid composition: Possible mechanism of bile acid induced biliary cholesterol desaturation. Gastroenterology, 1981, 81, 539-546.	0.6	39
70	MUTYH-associated polyposis (MAP): evidence for the origin of the common European mutations p.Tyr179Cys and p.Gly396Asp by founder events. European Journal of Human Genetics, 2014, 22, 923-929.	1.4	39
71	Descriptive epidemiology of colorectal cancer in Italy: The 6-year experience of a specialised registry. European Journal of Cancer, 1993, 29, 367-371.	1.3	36
72	Surgical management of the duodenal manifestations of familial adenomatous polyposis. British Journal of Surgery, 2011, 98, 480-484.	0.1	36

#	Article	IF	Citations
73	Bile acid feeding and hepatic sterol metabolism: Effect of deoxycholic acid. Gastroenterology, 1980, 79, 637-641.	0.6	35
74	Pattern of cell kinetics in colorectal mucosa of patients with different types of adenomatous polyps of the large bowel. Cancer, 1991, 68, 873-878.	2.0	34
<b>7</b> 5	Different molecular mechanisms underlie genomic deletions in theMLH1 Gene. Human Mutation, 2002, 20, 368-374.	1.1	34
76	Integrated analysis of unclassified variants in mismatch repair genes. Genetics in Medicine, 2011, 13, 115-124.	1,1	34
77	Impact of diabetes on overall and cancer-specific mortality in colorectal cancer patients. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1303-1310.	1.2	33
78	Assessment of pathogenicity criteria for constitutional missense mutations of the hereditary nonpolyposis colorectal cancer genes MLH1 and MSH2. European Journal of Human Genetics, 1999, 7, 778-782.	1.4	31
79	Different phenotypes in Muir-Torre syndrome: clinical and biomolecular characterization in two Italian families. British Journal of Dermatology, 2005, 152, 1335-1338.	1.4	31
80	Clinical outcome of low- and high-risk malignant colorectal polyps: results of a population-based study and meta-analysis of the available literature. Internal and Emergency Medicine, 2014, 9, 151-160.	1.0	29
81	Biologic Characterization of Hereditary Non-Polyposis Colorectal Cancer: <i>Nuclear Ploidy, AgNOR Count, Microvessel Distribution, Oncogene Expression, and Grade-Related Parameters</i> Journal of Clinical Pathology, 1995, 103, 265-270.	0.4	28
82	Survival in Adult Italian Cancer Patients, 1978–1989. Tumori, 1997, 83, 39-425.	0.6	28
83	Variations in the Survival of Adult Cancer Patients in Italy. Tumori, 1997, 83, 497-504.	0.6	28
84	Epidemiology of colorectal cancer: the 21-year experience of a specialised registry. Internal and Emergency Medicine, 2007, 2, 269-279.	1.0	27
85	Relationship between MUC5AC and altered expression of MLH1 protein in mucinous and non-mucinous colorectal carcinomas. Pathology Research and Practice, 2004, 200, 371-377.	1.0	26
86	Regional inequalities in cancer care persist in Italy and can influence survival. Cancer Epidemiology, 2012, 36, 541-547.	0.8	26
87	The effect of family size on estimates of the frequency of hereditary non-polyposis colorectal cancer. British Journal of Cancer, 1995, 72, 1320-1323.	2.9	25
88	Prevalence of Hereditary Nonpolyposis Colorectal Carcinoma (HNPCC). Annals of Medicine, 1994, 26, 209-214.	1.5	24
89	Mutations of the 'minor' mismatch repair gene MSH6 in typical and atypical hereditary nonpolyposis colorectal cancer. Familial Cancer, 2001, 1, 95-101.	0.9	24
90	Immunohistochemical Expression of MYH Protein Can Be Used to Identify Patients With MYH-Associated Polyposis. Gastroenterology, 2006, 131, 439-444.	0.6	24

#	Article	IF	Citations
91	Neutrophil gelatinase-associated lipocalin (NGAL) and matrix metalloproteinase-9 (MMP-9) prognostic value in stage I colorectal carcinoma. Pathology Research and Practice, 2011, 207, 479-486.	1.0	24
92	Lymphatic vessel density and its prognostic value in stage I colorectal carcinoma. Journal of Clinical Pathology, 2011, 64, 6-12.	1.0	24
93	Genetic epidemiology of hereditary non-polyposis colorectal cancer syndromes in Modena, Italy: results of a complex segregation analysis. Annals of Human Genetics, 1994, 58, 275-295.	0.3	23
94	Cancer Patient Survival in the Elderly in Italy. Tumori, 1997, 83, 490-496.	0.6	23
95	Stage I colorectal carcinoma: VEGF immunohistochemical expression, microvessel density, and their correlation with clinical outcome. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 457, 11-19.	1.4	23
96	Risk of cancer revealed by follow-up of families with hereditary non-polyposis colorectal cancer: A population-based study. International Journal of Cancer, 1993, 55, 202-207.	2.3	22
97	Familial aggregation of tumors and detection of hereditary non-polyposis colorectal cancer in 3-year experience of 2 population-based colorectal-cancer registries. International Journal of Cancer, 1995, 62, 685-690.	2.3	22
98	First observation of microadenomas in the ileal mucosa of patients with familial adenomatous polyposis and colectomies. Gastroenterology, 1995, 109, 374-380.	0.6	22
99	Colon cancer prevalence and estimation of differing care needs of colon cancer patients. Annals of Oncology, 2004, 15, 1136-1142.	0.6	22
100	A founder MLH1 mutation in families from the districts of Modena and Reggio-Emilia in northern Italy with hereditary non-polyposis colorectal cancer associated with protein elongation and instability. Journal of Medical Genetics, 2004, 41, 34e-34.	1.5	22
101	Lymph node micrometastasis and survival of patients with Stage I (Dukes' A) colorectal carcinoma. Scandinavian Journal of Gastroenterology, 2011, 46, 881-886.	0.6	22
102	<i>MLH1</i> constitutional and somatic methylation in patients with MLH1 negative tumors fulfilling the revised Bethesda criteria. Epigenetics, 2014, 9, 1431-1438.	1.3	22
103	Cholesterol absorption in cirrhosis: The role of total and individual bile acid pool size. Gastroenterology, 1981, 80, 1428-1437.	0.6	21
104	Variations in survival for invasive cervical cancer among European women, 1978-89. EUROCARE Working Group. Cancer Causes and Control, 1999, 10, 575-581.	0.8	21
105	Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients. Scandinavian Journal of Gastroenterology, 2012, 47, 1211-1217.	0.6	21
106	MSH3 Protein Expression and Nodal Status in MLH1-Deficient Colorectal Cancers. Clinical Cancer Research, 2012, 18, 3142-3153.	3.2	21
107	Incidence and survival of patients with Dukes' A (stages T1 and T2) colorectal carcinoma: a 15-year population-based study. International Journal of Colorectal Disease, 2005, 20, 147-154.	1.0	20
108	Autoradiographic and flow-cytometric assessment of cell proliferation in primary colorectal cancer: Relationship to dna ploidy and clinico-pathological features. International Journal of Cancer, 1992, 50, 719-723.	2.3	19

#	Article	IF	CITATIONS
109	Cell kinetics evaluation of colorectal tumors afterin vivo administration of bromodeoxyuridine. International Journal of Cancer, 1992, 52, 856-861.	2.3	19
110	Role of clinical criteria in the diagnosis of hereditary non-polyposis colorectal cancer (HNPCC): Results of a multivariate analysis. International Journal of Cancer, 1994, 58, 799-802.	2.3	19
111	Genomic instability and target gene mutations in colon cancers with different degrees of allelic shifts., 2000, 27, 424-429.		19
112	Clinical and biologic heterogeneity of hereditary nonpolyposis colorectal cancer. International Journal of Cancer, 2001, 95, 323-328.	2.3	19
113	Relative role of <i> APC </i> and <i> MUTYH </i> mutations in the pathogenesis of familial adenomatous polyposis. Scandinavian Journal of Gastroenterology, 2009, 44, 1092-1100.	0.6	17
114	Frequency of constitutional <i>MSH6 </i> mutations in a consecutive series of families with clinical suspicion of HNPCC. Clinical Genetics, 2007, 72, 230-237.	1.0	16
115	Clinical features, frequency and prognosis of Dukes' A colorectal carcinoma: A population-based investigation. European Journal of Cancer, 1996, 32, 1957-1962.	1.3	15
116	Descriptive Epidemiology of Hereditary Non-Polyposis Colorectal Cancer. Tumori, 1996, 82, 102-106.	0.6	15
117	Small bowel carcinoma in hereditary nonpolyposis colorectal cancer. American Journal of Gastroenterology, 1998, 93, 2219-2222.	0.2	15
118	Decrease in plasma tryptophan after a tryptophan-free amino acid solution. A comparison between cirrhotic and control subjects. Life Sciences, 1991, 48, 409-418.	2.0	14
119	Clinical and Biologic Features of Adenomatosis Coli in Northern Italy. Scandinavian Journal of Gastroenterology, 1995, 30, 771-779.	0.6	14
120	Long-term survey of patients with curable colorectal cancer with specific reference to the quality of life. Internal and Emergency Medicine, 2011, 6, 529-535.	1.0	14
121	Matrix metalloproteinases 15 and 19 are stromal regulators of colorectal cancer development from the early stages. International Journal of Oncology, 2012, 41, 260-6.	1.4	14
122	PLZF Expression during Colorectal Cancer Development and in Normal Colorectal Mucosa according to Body Size, as Marker of Colorectal Cancer Risk. Scientific World Journal, The, 2013, 2013, 1-9.	0.8	14
123	Whipple's disease in a father-son pair. Internal and Emergency Medicine, 2006, 1, 254-256.	1.0	13
124	Attitude of the Italian general population towards prevention and screening of the most common tumors, with special emphasis on colorectal malignancies. Internal and Emergency Medicine, 2009, 4, 213-220.	1.0	13
125	Clinical features and colorectal cancer survival: An attempt to explain differences between two different Italian regions. European Journal of Cancer, 2010, 46, 142-149.	1.3	13
126	Incidence trend of malignant polyps through the data of a specialized colorectal cancer registry: clinical features and effect of screening. Scandinavian Journal of Gastroenterology, 2013, 48, 1294-1301.	0.6	13

#	Article	IF	CITATIONS
127	Lymph node evaluation in stage IIA colorectal cancer and its impact on patient prognosis: A population-based study. Acta Oncol $\tilde{A}^3$ gica, 2013, 52, 1682-1690.	0.8	13
128	Morphological and quantitative analysis of BCL6 expression in human colorectal carcinogenesis. Oncology Reports, 2014, 31, 103-110.	1.2	13
129	Correlation between bromodeoxyuridine labelling and ornithine decarboxylase levels in normal rectal mucosa of patients with colorectal adenoma. Cancer Letters, 1991, 59, 221-224.	3.2	12
130	310 basepair APC deletion with duplication of breakpoint (4394ins 15del310) in an Italian polyposis patient. Human Mutation, 1998, 11, S220-S222.	1.1	12
131	Identification and Classification of Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome): Adapting Old Concepts to Recent Advancements. Report from the Italian Association for the Study of Hereditary Colorectal Tumors Consensus Group. Diseases of the Colon and Rectum, 2007, 50, 2126-2134.	0.7	12
132	Differentiated Thyroid Carcinoma (DTC) in a Young Woman with Peutz-Jeghers Syndrome: Are these Two Conditions Associated?. Experimental and Clinical Endocrinology and Diabetes, 2009, 117, 234-239.	0.6	12
133	Analysis of telomere dynamics in peripheral blood cells from patients with Lynch syndrome. Cancer, 2011, 117, 4325-4335.	2.0	12
134	Clinical and molecular features of attenuated adenomatous polyposis in northern Italy. Techniques in Coloproctology, 2013, 17, 79-87.	0.8	12
135	Gallstone Dissolution after 6 Months of Ursodeoxycholic Acid (UDCA): Effectiveness of Different Doses. Journal of International Medical Research, 1982, 10, 59-63.	0.4	11
136	Double heterozygosity for BRCA1 and hMLH1 gene mutations in a 46-year-old woman with five primary tumors. Techniques in Coloproctology, 2014, 18, 285-289.	0.8	11
137	Hereditary Nonpolyposis Colorectal Cancer: An Approach to the Selection of Candidates to Genetic TestingBased on Clinical and MolecularCharacteristics. Public Health Genomics, 1998, 1, 229-236.	0.6	10
138	Genotype-phenotype correlations in individuals with a founder mutation in the MLH1 gene and hereditary non-polyposis colorectal cancer. Scandinavian Journal of Gastroenterology, 2007, 42, 746-753.	0.6	10
139	Analysis of mismatch repair gene mutations in Turkish HNPCC patients. Familial Cancer, 2010, 9, 365-376.	0.9	10
140	Effect of small doses of deoxycholic acid on bile cholesterol saturation in patients with liver cirrhosis Gut, 1986, 27, 23-28.	6.1	9
141	Phenotype-genotype correlations in an extended family with adenomatosis coli and an unusual APC gene mutation. Diseases of the Colon and Rectum, 2001, 44, 1597-1604.	0.7	9
142	Survival, surgical management and perioperative mortality of colorectal cancer in the 21-year experience of a specialised registry. International Journal of Colorectal Disease, 2009, 24, 777-788.	1.0	9
143	Neutrophil gelatinase–associated lipocalin: a new prognostic marker in stage I colorectal carcinoma?. Human Pathology, 2011, 42, 1720-1726.	1.1	9
144	Duodenal carcinoma in a 37-year-old man with Cowden/Bannayan syndrome. Digestive and Liver Disease, 2013, 45, 75-78.	0.4	9

#	Article	IF	CITATIONS
145	The perception of health-related quality of life in colon cancer patients during chemotherapy: differences between men and women. Internal and Emergency Medicine, 2015, 10, 423-429.	1.0	9
146	Definition and management of colorectal polyposis not associated with APC/MUTYH germline pathogenic variants: AIFEG consensus statement. Digestive and Liver Disease, 2021, 53, 409-417.	0.4	9
147	Prognostic Relevance of MLH1 and MSH2 Mutations in Hereditary Non-Polyposis Colorectal Cancer Patients. Tumori, 2009, 95, 731-738.	0.6	8
148	Th Inducing POZ-Kruppel Factor (ThPOK) Is a Key Regulator of the Immune Response since the Early Steps of Colorectal Carcinogenesis. PLoS ONE, 2013, 8, e54488.	1.1	8
149	Clinical features of colorectal cancer patients in advanced age: a population-based approach. Internal and Emergency Medicine, 2016, 11, 191-197.	1.0	8
150	Inheritance and susceptibility to tumours of the large bowel: A new classification of colorectal malignancies. European Journal of Cancer, 1996, 32, 2206-2211.	1.3	7
151	The Prevalence of Colorectal Cancer in Italy. Tumori, 1999, 85, 387-390.	0.6	7
152	Endoscopic Papillectomy for Ampullary Adenomas: Different Outcomes in Sporadic Tumors and Those Associated with Familial Adenomatous Polyposis. Journal of Gastrointestinal Surgery, 2021, 25, 457-466.	0.9	7
153	Incidence, clinical features and possible etiology of early onset (â‰40Âyears) colorectal neoplasms. Internal and Emergency Medicine, 2013, 9, 623-31.	1.0	6
154	Attenuated polyposis of the large bowel: a morphologic and molecular approach. Familial Cancer, 2017, 16, 211-220.	0.9	6
155	Cholesterol esterase activity of human intestinal mucosa. Digestive Diseases and Sciences, 1985, 30, 1053-1064.	1.1	5
156	O6-methylguanine-DNA methyltransferase promoter hypermethylation in colorectal carcinogenesis. Oncology Reports, 2007, 17, 1421.	1.2	5
157	Disease presentation, treatment and survival for Italian colorectal cancer patients: a EUROCARE high resolution study. European Journal of Public Health, 2014, 24, 98-100.	0.1	5
158	Clinical and molecular characterization of colorectal cancer in young Moroccan patients. Turkish Journal of Gastroenterology, 2012, 23, 686-690.	0.4	5
159	Linkage studies in Italian families with familial adenomatous polyposis. Human Genetics, 1993, 90, 545-550.	1.8	4
160	Impact of Surgery on the Development of Duodenal Cancer in Patients with Familial Adenomatous Polyposis. Diseases of the Colon and Rectum, 2006, 49, 1860-1866.	0.7	4
161	Investigation of APC Mutations in a Turkish Familial Adenomatous Polyposis Family by Heterodublex Analysis. Diseases of the Colon and Rectum, 2005, 48, 567-571.	0.7	3
162	What should we advise about alcohol consumption. Internal and Emergency Medicine, 2011, 6, 87-87.	1.0	3

#	Article	IF	Citations
163	Looking at Differences in Stage and Treatment of Colorectal Cancers across Italy: A EUROCARE-5 High Resolution Study. Tumori, 2012, 98, 671-677.	0.6	3
164	Colonoscopic surveillance of first-degree relatives of colorectal cancer patients in a faecal occult blood screening programme. Cancer Epidemiology, 2013, 37, 469-473.	0.8	3
165	A case of pneumatosis cystoides intestinalis mimicking familial adenomatous polyposis. Familial Cancer, 2013, 12, 573-576.	0.9	3
166	An unusual case of familial adenomatous polyposis with very early symptom occurrence. Familial Cancer, 2014, 13, 375-380.	0.9	3
167	Chronic active hepatitis. Digestive Diseases and Sciences, 1981, 26, 957-958.	1.1	2
168	Problems in the identification of hereditary nonpolyposis colorectal cancer in two families with late development of full-blown clinical spectrum. American Journal of Gastroenterology, 2000, 95, 2110-2115.	0.2	2
169	Adjuvant Chemotherapy in Colorectal Cancer Patients with Microsatellite Instability. Clinical Cancer Research, 2006, 12, 3866-3867.	3.2	2
170	Risk of colorectal polyps and of malignancies in asymptomatic carriers of mutations in the main DNA mismatch repair genes. Scandinavian Journal of Gastroenterology, 2018, 53, 31-37.	0.6	2
171	Hereditary Non-polyposis Colorectal Cancer (Lynch Syndrome)., 2002,, 191-224.		2
172	Effect of Cicloxilic Acid on Bile Lipid Composition in Patients with Gallstones: A Multicenter Trial. Digestion, 1983, 28, 102-107.	1.2	1
173	Argyrophilic nucleolar organizer regions and bromodeoxyuridine and3[H]-thymidine labelling indices in colorectal cancer. Cell Proliferation, 1995, 28, 471-480.	2.4	1
174	Recommendations for Clinical Management of Familial Adenomatous Polyposis. Tumori, 1997, 83, 800-803.	0.6	1
175	The obesity epidemic. QJM - Monthly Journal of the Association of Physicians, 2005, 98, 234-234.	0.2	1
176	What clinicians wish to know about benign colorectal polyps: An operative classification. Pathology Research and Practice, 2014, 210, 645-648.	1.0	1
177	Genomic instability and target gene mutations in colon cancers with different degrees of allelic shifts. , 2000, 27, 424.		1
178	Looking at differences in stage and treatment of colorectal cancers across Italy: a EUROCARE-5 high resolution study. Tumori, 2012, 98, 671-7.	0.6	1
179	Risk of cancer revealed by follow-up of families with hereditary non-polyposis colorectal cancer: Reply to Dr. Eluf-Neto. International Journal of Cancer, 1995, 61, 744-744.	2.3	O
180	Mismatch Repair Gene Mutations in Iranian HNPCC Families. American Journal of Gastroenterology, 2007, 102, S559.	0.2	0

#	Article	IF	CITATIONS
181	The Causes of Colorectal Cancer. , 2002, , 1-22.		O
182	Familial Adenomatous Polyposis. , 2002, , 225-251.		0
183	Pathogenesis of Colorectal Cancer. , 2002, , 23-48.		O
184	Other Polyposis of the Large Bowel. , 2002, , 253-274.		0
185	Survival and Follow-up of Colorectal Cancer. , 2002, , 163-179.		O
186	Pathology of Colorectal Cancer. , 2002, , 49-78.		0
187	Colorectal Cancer Screening and Surveillance. , 2002, , 95-115.		O
188	Prevention and Chemoprevention of Colorectal Neoplasms. , 2002, , 117-133.		0
189	Estimates of cancer burden in Emilia-Romagna. Tumori, 2013, 99, 327-33.	0.6	O